Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Cancer
Status:
Recruiting
Trial end date:
2025-06-01
Target enrollment:
Participant gender:
Summary
This phase III trial studies how well chemotherapy and radiation therapy work with or without
atezolizumab in treating patients with localized muscle invasive bladder cancer. Radiation
therapy uses high energy rays to kill tumor cells and shrink tumors. Chemotherapy drugs, such
as gemcitabine, cisplatin, fluorouracil and mitomycin-C, work in different ways to stop the
growth of cancer cells, either by killing the cells, by stopping them from dividing, or by
stopping them from spreading. Giving chemotherapy with radiation therapy may kill more tumor
cells. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's
immune system attack the cancer, and may interfere with the ability of tumor cells to grow
and spread. Giving atezolizumab with radiation therapy and chemotherapy may work better in
treating patients with localized muscle invasive bladder cancer compared to radiation therapy
and chemotherapy without atezolizumab.